|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 5.390 USD | -4.09% |
|
-10.17% | -53.73% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: ARS Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 799.9 | 526.1 | 1,025 | 1,152 | 558.9 | - | - |
| Change | - | -34.23% | 94.9% | 12.32% | -51.47% | - | - |
| Enterprise Value (EV) | 525.5 | 297.7 | 1,025 | 1,152 | 558.9 | 558.9 | 558.9 |
| Change | - | -43.35% | 244.4% | 12.32% | -51.47% | 0% | 0% |
| P/E | -9.8x | -9.61x | 132x | -6.7x | -2.91x | -6.38x | 108x |
| PBR | - | - | - | - | - | - | - |
| PEG | -2.03x | 0.3x | -1x | 0x | -0.46x | 0.1x | -1x |
| Capitalization / Revenue | 608x | 17,535x | 11.5x | 13.7x | 4.3x | 2.93x | 1.93x |
| EV / Revenue | 0x | 0.01x | 0x | 0x | 4.3x | 2.93x | 1.93x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -3.02x | -6.6x | 102x |
| EV / FCF | - | - | 0x | -0x | -2.91x | -10.1x | 11.2x |
| FCF Yield | - | - | 1.27% | -14.9% | -34.4% | -9.9% | 8.96% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.87 | -0.57 | 0.08 | -1.74 | -1.85 | -0.845 | 0.05 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.316 | 0.03 | 89.15 | 84.28 | 129.9 | 190.6 | 290.3 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -35.52 | -67.52 | -3.083 | -179.4 | -185.3 | -84.67 | 5.48 |
| Net income 1 | -34.68 | -54.36 | 7.998 | -171.3 | -184 | -85.02 | 9.032 |
| Net Debt | -274.4 | -228.4 | - | - | - | - | - |
| Reference price 2 | 8.530 | 5.480 | 10.550 | 11.650 | 5.390 | 5.390 | 5.390 |
| Nbr of stocks (in thousands) | 93,770 | 95,997 | 97,185 | 98,849 | 99,447 | - | - |
| Announcement Date | 3/23/23 | 3/21/24 | 3/20/25 | 3/9/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.08x | - | - | - | 559M | |
| 32.76x | 5.88x | 17.63x | 0.99% | 48.41B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.43x | 29.72x | -.--% | 40.73B | |
| 28.26x | 8.5x | 21.55x | 0.4% | 33.21B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 23.87x | 2.08x | 9x | 1.13% | 14.45B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 28.06x | 35.05x | 13.73x | 0.32% | 28.53B | |
| Weighted average by Cap. | 27.07x | 47.50x | 12.21x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRY Stock
- Valuation ARS Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
